Eggert Stockfleth, MD In this presentation, Dr Stockfleth reviews the latest data and the role of the human papillomavirus (HPV) in skin cancer. We know that HPV is very stable. The virus is host specific and has a very special DNA from the oncogenic type (E6 and E7). HPV is approximately 45-55 nm in size […]
Derek Jones, MD In this presentation, Dr Jones reviews the data on Belotero, a novel therapeutic approach to dermal fillers. CPM Technology Belotero utilizes CPM Technology. This is the most important difference with regards to Belotero and other dermal fillers. Belotero utilizes CPM Technology, a key differentiator between Belotero and other hyaluronic acid dermal fillers. […]
Joel Cohen, MD In this presentation, Dr Cohen reviews the complications that can occur when utilizing fillers and best practices on how to manage these various complications. Dermatologists use fillers across the world, millions of times per year, and most of the time, everything is fine; but understanding the complications and how to manage them […]
Wm. Philip Werschler, MD In this presentation, Dr Werschler provides an overview of the fillers currently available on the market by class and by product, and how they can be utilized in clinical practice along with some key takeaway points for clinicians. How did we get here today? Beginning in 1981, bovine collagen was introduced […]
Michael Gold, MD Dermatologists should be aware that the global medical aesthetic market is expected to grow 10.8% per year between 2010 an 2015 and many other companies are joining the toxin “band-wagon”. Products Under Development/Currently Approved in Other Countries Medy-Tox – Neuronox (South American and Korea) Siax – Neuronox (Colombia) ChinaTox –Lanzhou Biological Products […]
Joel Cohen, MD Upper Face: “The Big 3” Botox, Dysport, and Xeomin are all FDA approved for glabellar lines. The products are also used for the forehead and crow’s feet. Dangers Dermatologists should be cautious of the dangers associated with delivering fillers and toxins simultaneously. Dosing Data suggest that higher botulinum toxin type A […]
Joel Cohen, MD In this presentation, Dr Cohen reviews the use of botulinum toxins in clinical practice. He reviews the three Type A toxins such as Botox, Dysport, and Xeomin. Science and Data To Be Considered It is important that clinicians understand the molecular structure of Botulinum neurotoxin type A. The core neurotoxin protein in […]
Bruce Strober, MD, PhD Case Study 1 – IL-12/23 Inhibitors 54 year-old man Severe psoriasis affecting 25% BSA, PGA = 3 No psoriatic arthritis Failure to respond to: Methotrexate 20 mg weekly for 12 weeks Etanercept (primary failure) Adalimumab (primary failure) Infliximab (initial response, with subsequent failure) History of: Hypertension Hypercholesterolemia Hypertriglyceridemia Obese, 120 […]
Written by: Judy Seraphine Based Upon a Presentation Delivered by Arthur Kavanaugh, MD at the 2012 Maui Derm Introduction B cells may play a prominent role in a number of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, pemphigus/pemphigoid, vasculitis, and many others. The mechanisms by which B cells may play a role in autoimmunity […]
Sheila Fallon Friedlander, MD Dr Friedlander reviews the many questions that face clinicians regarding vitamin D in their pediatric patients. Patients still come in and ask and about what do regarding Vitamin D and sun protection; as dermatologists it is important to provide them with accurate and useful information. Historical Perspective Why do we or […]
Administrative Office
Maui Derm
161 Wailea Ike Place, Suite A-104
Kihei, HI 96753
Stay Connected
Sign up to receive updates about upcoming meetings.